Latham & Watkins Advises Bridgepoint in Acquisition of RoC Skincare

Bridgepoint has announced that Bridgepoint Europe VII (BE VII), a fund focused on investing in mid-market growth businesses, has made a strategic investment in RoC Skincare, the iconic skincare brand. RoC’s existing backer, Gryphon Investors, will sell its majority shareholding in RoC to Bridgepoint as part of the transaction. Financial terms were not disclosed.

Latham & Watkins LLP advised Bridgepoint in the transaction with a corporate deal team led by New York partners David Allinson and Jane Greyf and Paris partner Olivier du Mottay, with associates Saïd Bakir, Sami El-Kebbi, Daniel Maggen, and Jee Yun (Jen) Oh. Advice was also provided on benefits matters by New York partner Bradd Williamson and Chicago counsel Leah Segall, with associate Victoria Wolfe; on finance matters by Washington, D.C. partner Jeffrey Chenard, with associate Kayla Van Wyngarden; on US tax matters by New York partner Eric Kamerman, with associate Ron Moore; on French tax matters by Paris partner Olivia Rauch-Ravisé, with associate Jean-Baptiste Bourbier; on IP matters by New York partner Steven Betensky, with associate Ryan Wilkins; on data privacy matters by Bay Area partner Robert Blamires, with associates Kathryn Parsons-Reponte and Dyllan Brown-Bramble; on FTC compliance matters by Washington, D.C. partner Jennifer Archie; on US antitrust matters by Bay Area partner Joshua Holian and Washington, D.C. counsel Joseph Simei, with associate Hanna Nunez Tse; on EU antitrust matters by Brussels/London partner David Little, with associates Oscar Hayward and James Mathieson; on EU healthcare regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with associates Jeanne Fabre and Ranulf Barman; on US healthcare regulatory matters by Washington, D.C. counsel Chad Jennings; on CFIUS matters by Washington, D.C. partner Jim Barker; and on insurance matters by Los Angeles partners Drew Levin and Harrison White, with associate Enrique Covarrubias.